These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

370 related articles for article (PubMed ID: 15121047)

  • 1. Vesicular stomatitis virus: re-inventing the bullet.
    Lichty BD; Power AT; Stojdl DF; Bell JC
    Trends Mol Med; 2004 May; 10(5):210-6. PubMed ID: 15121047
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Vesicular stomatitis virus in the fight against cancer].
    Janelle V; Poliquin L; Lamarre A
    Med Sci (Paris); 2013 Feb; 29(2):175-82. PubMed ID: 23452604
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Natural and genetically engineered viral agents for oncolysis and gene therapy of human cancers.
    Sinkovics JG; Horvath JC
    Arch Immunol Ther Exp (Warsz); 2008 Dec; 56 Suppl 1():3s-59s. PubMed ID: 19104757
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Enhanced oncolytic activity of vesicular stomatitis virus encoding SV5-F protein against prostate cancer.
    Chang G; Xu S; Watanabe M; Jayakar HR; Whitt MA; Gingrich JR
    J Urol; 2010 Apr; 183(4):1611-8. PubMed ID: 20172545
    [TBL] [Abstract][Full Text] [Related]  

  • 5. VSV-tumor selective replication and protein translation.
    Barber GN
    Oncogene; 2005 Nov; 24(52):7710-9. PubMed ID: 16299531
    [TBL] [Abstract][Full Text] [Related]  

  • 6. United virus: the oncolytic tag-team against cancer!
    Le Boeuf F; Bell JC
    Cytokine Growth Factor Rev; 2010; 21(2-3):205-11. PubMed ID: 20227326
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Oncolytic enteroviruses].
    Chumakov PM; Morozova VV; Babkin IV; Baĭkov IK; Netesov SV; Tikunova NV
    Mol Biol (Mosk); 2012; 46(5):712-25. PubMed ID: 23156670
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Vesicular stomatitis virus as a flexible platform for oncolytic virotherapy against cancer.
    Hastie E; Grdzelishvili VZ
    J Gen Virol; 2012 Dec; 93(Pt 12):2529-2545. PubMed ID: 23052398
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antibody-mediated enhancement of the rate, magnitude, and responsiveness of vesicular stomatitis virus induced alpha interferon production.
    Green DS; Lum T; Mullins BT; Green JA
    J Med Virol; 2008 Sep; 80(9):1675-83. PubMed ID: 18649334
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Oncolytic virus therapy using vesicular stomatitis virus].
    Ebert O
    Dtsch Med Wochenschr; 2009 Oct; 134(44):2236-8. PubMed ID: 19847736
    [No Abstract]   [Full Text] [Related]  

  • 11. Experimental Evolution Generates Novel Oncolytic Vesicular Stomatitis Viruses with Improved Replication in Virus-Resistant Pancreatic Cancer Cells.
    Seegers SL; Frasier C; Greene S; Nesmelova IV; Grdzelishvili VZ
    J Virol; 2020 Jan; 94(3):. PubMed ID: 31694943
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cell Cycle Arrest in G
    Bressy C; Droby GN; Maldonado BD; Steuerwald N; Grdzelishvili VZ
    J Virol; 2019 Feb; 93(4):. PubMed ID: 30487274
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Oncolytic vesicular stomatitis viruses are potent agents for intravesical treatment of high-risk bladder cancer.
    Hadaschik BA; Zhang K; So AI; Fazli L; Jia W; Bell JC; Gleave ME; Rennie PS
    Cancer Res; 2008 Jun; 68(12):4506-10. PubMed ID: 18559493
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Therapeutic potential of oncolytic measles virus: promises and challenges.
    Galanis E
    Clin Pharmacol Ther; 2010 Nov; 88(5):620-5. PubMed ID: 20881957
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Combining oncolytic virotherapy and tumour vaccination.
    Bridle BW; Hanson S; Lichty BD
    Cytokine Growth Factor Rev; 2010; 21(2-3):143-8. PubMed ID: 20226716
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The strength of the T cell response against a surrogate tumor antigen induced by oncolytic VSV therapy does not correlate with tumor control.
    Janelle V; Langlois MP; Lapierre P; Charpentier T; Poliquin L; Lamarre A
    Mol Ther; 2014 Jun; 22(6):1198-1210. PubMed ID: 24590047
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Propagation, purification, and in vivo testing of oncolytic vesicular stomatitis virus strains.
    Diallo JS; Vähä-Koskela M; Le Boeuf F; Bell J
    Methods Mol Biol; 2012; 797():127-40. PubMed ID: 21948474
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Virus specific tolerance enhanced efficacy of cancer immuno-virotherapy.
    Sobhanimonfared F; Bamdad T; Sadigh ZA; Choobin H
    Microb Pathog; 2020 Mar; 140():103957. PubMed ID: 31891795
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Vesicular Stomatitis Virus (VSV) G Glycoprotein Can Be Modified to Create a Her2/Neu-Targeted VSV That Eliminates Large Implanted Mammary Tumors.
    Gao Y; Bergman I
    J Virol; 2023 Jun; 97(6):e0037223. PubMed ID: 37199666
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Retargeting Oncolytic Vesicular Stomatitis Virus to Human T-Cell Lymphotropic Virus Type 1-Associated Adult T-Cell Leukemia.
    Betancourt D; Ramos JC; Barber GN
    J Virol; 2015 Dec; 89(23):11786-800. PubMed ID: 26378177
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.